Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

avet health limited - ampicillin trihydrate; cloxacillin as the benzathine salt - misc. intra mammary - ampicillin trihydrate antibiotic active 250.0 mg/sg; cloxacillin as the benzathine salt antibiotic active 500.0 mg/sg - antibiotic & related - cow-not lactating-preg. not w/i 1mth cal | dairy cattle dry | dairy cattle lactating | bovine | cow | cow pregnant not within 1 - antibiotic - anti-infective | abrasions | abscesses | airsacculitis | antiseptic | avian mycoplasmas | blackhead | body odours | bowed tendons | broad spectrum | burns | coccidiosis | coliform complex | conjunctivitis | cowpox | cracks | crusts | dandruff | dermatological disorders | dermatosis | dry skin | dysentery | eczema | endometritis | enteric diseases | enzootic pneumonia | feed efficiency | fungal infections | girth galls | infections | inflammed pads | itching | keratolytic | lacerations | mastitis | mycoplasmas | odours | open wounds | otitis | pruritis | queensland itch | respiratory disease | saddle rash | salmonellosis | scabs | scaly skin | sheath rot | skin irritations | sores | swine dysentery | teat cracking | teat infections | topical infections | udder sores | weight gain | wire cuts | wounds

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratoire aguettant - zinc gluconate - concentrate for soln for inf - 1 mg/ml - other mineral supplements - mineral supplements - supplementation solution in prolonged parenteral nutrition and in situations where a pronounced deficiency may occur: e.g. severe malnutrition, hypercatabolism, digestive fistula, chronic diarrhoea.

Ireland - English - HPRA (Health Products Regulatory Authority)

provimi ltd - zinc oxide - premix for medicated feeding stuff - 100 percent - zinc oxide - pigs - miscellaneous

United States - English - NLM (National Library of Medicine)

phoenix pharmaceutical, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - neomycin sulfate 3.5 mg in 1 g - neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology). the particular anti-infective drugs in this product

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), hydrocortisone acetate (unii: 3x7931po74) (hydrocortisone - unii:wi4x0x7bpj) - neomycin sulfate 3.5 mg in 1 g - neomycin and polymyxin b sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology ). the particular anti-infect

United States - English - NLM (National Library of Medicine)

henry schein inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - neomycin 3.5 mg in 1 g - neomycin and polymyxin b sulfates, bacitracin zinc, and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology ). the particular anti-infective drugs in this produ

United States - English - NLM (National Library of Medicine)

luzern laboratories, inc - zinc oxide (ci 77947) 15% - zinc oxide 15 g in 100 ml - sunscreen helps prevent sunburn

United States - English - NLM (National Library of Medicine)

hameln pharma gmbh - pentetate zinc trisodium (unii: nxu65ic8pg) (pentetic acid - unii:7a314hqm0i) - pentetate zinc trisodium 1000 mg in 5 ml - zn-dtpa is indicated for treatment of individuals with known or suspected internal contamination with plutonium, americium, or curium to increase the rates of elimination. none. pregnancy category b risk summary there are no adequate and well-controlled studies of zn-dtpa use in pregnant women. chelation treatment of pregnant women should begin and continue with zn-dtpa. reproduction studies have been performed in pregnant mice at doses up to 31 times (11.5 mmol/kg) the recommended daily human dose and have revealed no evidence of impaired fertility or harm to the fetus due to zn-dtpa. there was a slight reduction in the average birth weight. because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. it is not known whether zn-dtpa is excreted in human milk. radiocontaminants are known to be excreted in breast milk. women with known or suspected internal contamination with radiocontaminants should not breast feed, whether

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - zinc sulfate - oral capsule - 220mg

Australia - English - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - thiamine hydrochloride, quantity: 5 mg/ml; riboflavine sodium phosphate, quantity: 2.5 mg/ml; nicotinamide, quantity: 50 mg/ml; dexpanthenol, quantity: 10 mg/ml; pyridoxine hydrochloride, quantity: 25 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - b vitamin deficiencies may exist that are unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of b vitamins may be insufficient in; alcoholism, pernicious anaemia, malabsorption disorders, gastrectomy, gastrointestinal pathologies and debilitated and elderly patients. specific indications include: 1. rapid saturation of the b group vitamins. 2. when oral administration is not feasible or appropriate. 3. for alcoholic, debilitated and elderly patients when their diet is inadequate. 4. patients requiring parenteral b vitamin therapy who cannot tolerate intramuscular injections. 5. recovery from beriberi and wernicke's syndrome as a result of vitamin b1 deficiency. please note that iv b-dose 2ml injection does not contain sufficient thiamine for acute treatment of wernicke's syndrome. 6. pellagra as a result of vitamin b3 deficiency. patients with pellagra may have a concurrent deficiency of b1, b2 and b6. 7. peripheral neuritis caused by vari